FDA能量旋切安全通告背景下骶骨固定术中偶然发现子宫恶性肿瘤的研究
本研究回顾性分析2004年1月至2018年12月在美国一家三级转诊中心接受骶骨固定术的839例患者,其中238例(28.4%)同时行子宫切除术,无术前怀疑或确诊妇科恶性肿瘤。结果无子宫恶性肿瘤病例(0%,95%CI 0%-1.6%),有1例卵巢交界性肿瘤;2014年FDA能量旋切安全通告后子宫切除术式显著变化但为暂时性。
要点
- 骶骨固定术同时行子宫切除术者中,子宫恶性肿瘤发生率为0%(95%CI 0%-1.6%)。
- 2014年FDA通告后,子宫切除术式转为经阴道子宫切除术为主(n=35,55.6%;p<.001)。
- 通告后最初两年与随后两年相比,腹腔镜子宫切除术使用率显著增加(7.3% vs 40.9%;p<.001)。
核心结论
- 在接受骶骨固定术并同时行子宫切除术的患者队列中,子宫恶性肿瘤发生率低。
- FDA安全通告后子宫切除术式实践模式发生变化,但变化幅度是暂时的。
研究设计与样本
- 回顾性病历审查,美国一家三级转诊中心,纳入2004年1月至2018年12月接受骶骨固定术的839例患者。
- 所有患者同时行子宫切除术,术前无怀疑或确诊妇科恶性肿瘤。
- 比较2014年FDA能量旋切安全通告前后的手术趋势。
主要发现
- 238例(28.4%)在骶骨固定术时行子宫切除术。
- 无子宫恶性肿瘤病例(0%,95%CI 0%-1.6%),有1例卵巢交界性肿瘤。
- 15年间最常见子宫切除术式为腹腔镜子宫切除术(n=84,35.3%),其次为经阴道子宫切除术(n=63,26.5%)。
- FDA通告后,最常见子宫切除术式显著变为经阴道子宫切除术(n=35,55.6%;p<.001)。
- 通告后最初两年(2014-2016)与随后两年(2017-2018)相比,腹腔镜子宫切除术使用率显著增加(7.3% vs 40.9%;p<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: The objective of this study was to determine the incidence of occult uterine malignancy at the time of sacrocolpopexy with concurrent hysterectomy, in the context of practice pattern changes as a result of the 2014 Food and Drug Administration (FDA) power morcellation safety communication. DESIGN: Retrospective chart review. SETTING: Tertiary care referral center in the United States. PATIENTS: A total of 839 patients who underwent sacrocolpopexy from January 2004 to December 2018. INTERVENTIONS: All patients received a concurrent hysterectomy without a diagnosis of suspected or confirmed gynecologic malignancy before surgery. Trends of surgeries were compared before and after the 2014 FDA power morcellation safety communication. MEASUREMENTS AND MAIN RESULTS: Demographic and perioperative data were collected from the system-wide electronic medical record. Operative and pathology reports were reviewed to determine the method of specimen retrieval and specimen pathology results. A total of 238 patients (28.4%) had a hysterectomy at the time of sacrocolpopexy. There were no cases of occult uterine malignancy (0%, 95% CI 0%-1.6%). There was 1 case of borderline tumor of the ovary. The most common mode of hysterectomy over the 15-year period was laparoscopic hysterectomy (n = 84, 35.3%), followed by vaginal hysterectomy (n = 63, 26.5%). After the FDA communication, the most common form of hysterectomy changed significantly to vaginal hysterectomy (n = 35, 55.6%; p <.001). When comparing the first 2 years after the announcement (2014-2016) to the subsequent 2 years (2017-2018), there was again a significant increase in the use of laparoscopic hysterectomy in the latter time period (7.3% vs 40.9%; p <.001). CONCLUSION: In this cohort of patients undergoing sacrocolpopexy with concurrent hysterectomy, the incidence of occult uterine malignancy was low. After the FDA safety communication, practice patterns with regard to the mode of hysterectomy changed, but the magnitude of these changes were transient.
引用
- Chang OH, Ferrando CA. Occult Uterine Malignancy at the Time of Sacrocolpopexy in the Context of the Safety Communication on Power Morcellation by the FDA. J Minim Invasive Gynecol. 2020. PMID: 32681994. doi:10.1016/j.jmig.2020.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。